Literature DB >> 30027378

Linguistic abilities in major vascular cognitive impairment: a comparative study with Alzheimer's disease.

Maria Isabel D'Avila Freitas1,2, Claudia S Porto3, Maira O Oliveira3, Sonia M D Brucki3, Leticia L Mansur3,4, Ricardo Nitrini3, Marcia Radanovic3.   

Abstract

We assessed the linguistic abilities of multi-infarct (cortical) dementia and subcortical ischemic vascular dementia (VaD) patients and compared the linguistic performance of VaD and Alzheimer's Disease (AD) patients. A total of 23 VaD patients, 20 mild AD patients, and 31 controls participated in the study. All were evaluated using the Arizona Battery for Communication Disorders of Dementia (ABCD). Neuropsychological testing was performed to ascertain that VaD and AD patients had comparable cognitive performance. Both dementia groups performed more poorly than controls in the ABCD measures, except for the comparative question subtest. Comparison between VaD and AD patients showed statistically significant differences only in the confrontation naming subtest (p < 0.05), where paraphasias and visual errors were the most prevalent. AD patients showed a trend towards more circumlocution errors than VaD patients (p = 0.0483). When compared to controls, linguistic abilities of VaD patients were impaired in all measures of linguistic expression and linguistic comprehension, except for the comparative question subtest. Linguistic differences between VaD and AD patients were observed only in the confrontation naming subtest.

Entities:  

Keywords:  Alzheimer’s disease; Cognition; Elderly; Language; Vascular cognitive impairment

Mesh:

Year:  2018        PMID: 30027378     DOI: 10.1007/s13760-018-0977-x

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  1 in total

1.  The effectiveness of cognitive rehabilitation in improving visual and auditory attention in ischemic stroke patients.

Authors:  Samira Hasanzadeh Pashang; Hossein Zare; Ahmad Alipour; Mahdi Sharif-Alhoseini
Journal:  Acta Neurol Belg       Date:  2020-02-06       Impact factor: 2.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.